Elanco Animal Health Incorporated Deferred Federal Income Tax Expense (Benefit)
Elanco Animal Health Incorporated (ELAN) reported Deferred Federal Income Tax Expense (Benefit) of -$4.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-24
- Elanco Animal Health Incorporated deferred federal income tax expense (benefit) for fiscal 2025 was -$4.00M, a 500.00% decline from fiscal 2024.
- Elanco Animal Health Incorporated deferred federal income tax expense (benefit) for fiscal 2024 was $1.00M.
- Elanco Animal Health Incorporated deferred federal income tax expense (benefit) for fiscal 2023 was -$3.00M.
- Elanco Animal Health Incorporated deferred federal income tax expense (benefit) for fiscal 2022 was -$20.00M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$4.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $1.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | -$3.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | -$20.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | -$11.00M 10-K · filed 2024-02-26 | -$9.00M 10-K · filed 2022-02-28 |
| 2020-12-31 | -$6.00M 10-K · filed 2023-03-01 | -$8.00M 10-K · filed 2021-03-01 |
| 2019-12-31 | $15.00M 10-K · filed 2022-02-28 | $14.50M 10-K · filed 2020-02-28 |
| 2018-12-31 | -$56.80M 10-K · filed 2021-03-01 | |
| 2017-12-31 | $42.60M 10-K · filed 2020-02-28 | |
| 2016-12-31 | $18.40M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |